Financial Engines Advisors
PRTK

Financial Engines Advisors’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Financial Engines Advisors’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-40,000
Closed -$273K – 290
2021
Q2 		$273K Hold
40,000
– – ﹤0.01% 186
2021
Q1 		$282K Hold
40,000
– – ﹤0.01% 219
2020
Q4 		$250K Hold
40,000
– – ﹤0.01% 228
2020
Q3 		$216K Buy
+40,000
New +$198K ﹤0.01% 221

Other funds holding PRTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Financial Engines Advisors's PRTK Position: Q3 2021 in Review

Financial Engines Advisors sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2021, closing a stake of 40,000 shares — an estimated $273K sold.

Financial Engines Advisors first reported a position in PRTK in Q3 2020 and held it in 4 quarters. The position peaked at $282K in Q1 2021. 105 funds tracked by Wall St. Rank hold PRTK as of Q3 2021.

  • Financial Engines Advisors reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
  • Financial Engines Advisors sold 40,000 Paratek Pharmaceuticals, Inc. shares in Q3 2021, an estimated $273K.
  • Financial Engines Advisors first reported a position in Paratek Pharmaceuticals, Inc. in Q3 2020 and held it in 4 quarters.
  • Financial Engines Advisors's Paratek Pharmaceuticals, Inc. position peaked at $282K in Q1 2021.
  • 105 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2021.

Based on Financial Engines Advisors's 13F filing for Q3 2021, filed 12 Nov 2021.